Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1
Pharmaceutical Technology
MAY 2, 2024
Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
MAY 2, 2024
Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
Pharma Mirror
MAY 19, 2021
Azbil Telstar announces the appointment of Rashedi Hassan as a Sales & Marketing Manager of the subsidiary of the company in Dhaka, Bangladesh. The post Rashedi Hassan takes over Sales & Marketing management of Telstar’s subsidiary in Bangladesh appeared first on Pharma Mirror Magazine. With more than 18.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
AUGUST 8, 2023
The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.
Bio Pharma Dive
AUGUST 17, 2022
The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics.
BioSpace
APRIL 16, 2024
On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData.
Bio Pharma Dive
NOVEMBER 3, 2022
The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.
Pharma Mirror
OCTOBER 17, 2022
The post Artificial Intelligence (AI) in Pharma Sales and Marketing appeared first on Pharma Mirror Magazine. This could be used to determine target audiences, decide on optimal times to send emails, or segment out groupings for deeper engagement. Deep learning In.
Bio Pharma Dive
APRIL 2, 2024
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
Fierce Pharma
APRIL 5, 2024
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction than | Facing lackluster Cyltezo sales, Boehringer Ingelheim will prune its ranks in the U.S.
Fierce Pharma
MAY 6, 2024
As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward.
Pharma Mirror
JUNE 23, 2023
In the fast-paced, highly competitive pharmaceutical industry, sales reps must adapt to new ways of engaging with customers and healthcare professionals (HCPs).
BioSpace
APRIL 25, 2024
Humira maintained its blockbuster status and market share dominance in the first quarter of 2024, but experienced a drop in sales as biosimilar competition heated up, AbbVie reported on Friday.
Pharma Mirror
APRIL 14, 2021
The role of pharma sales reps is an incredibly important part of this lifecycle from initial research to point of sale and distribution, with reps connecting the groundbreaking research and technology of pharma companies with healthcare professionals and medical establishments.
Bio Pharma Dive
APRIL 18, 2023
Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.
Fierce Pharma
APRIL 23, 2024
The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales.
Pharma Marketing Network
JULY 19, 2023
Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry Content marketing is a long-term strategy that can help businesses of all sizes generate leads, increase brand awareness, and drive sales.
Bio Pharma Dive
JANUARY 31, 2023
The company expects yearly revenue from Comirnaty and Paxlovid to fall by nearly two thirds in 2023 amid lower vaccination rates and a shift to private market sales.
Pharmaceutical Technology
APRIL 28, 2023
Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn.
pharmaphorum
DECEMBER 23, 2022
Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer. In 2023, omnichannel behaviours will directly influence incentive compensation models by correlating successful engagement data to successful sales outcomes.
Bio Pharma Dive
OCTOBER 25, 2022
Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.
Fierce Pharma
MAY 1, 2024
Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen.
Pharmaceutical Technology
JANUARY 25, 2023
It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022.
Pharma Marketing Network
APRIL 21, 2021
The Pharma Marketing Podcast is pleased to present this special guest episode from our friend and Editorial Advisory Board member Darshan Kulkarni, Sales and Marketing Oversight – April 21, 2021. Darshan Kulkarni and Marc Banjak, General Counsel at Dova Pharmaceuticals, discuss sales compliance in the life sciences.
Pharmaceutical Technology
MARCH 30, 2023
The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. This would make Leqembi’s forecast sales 17 times greater than those of Aricept.
BioSpace
JUNE 7, 2022
Sales and marketing roles in the life sciences field are in high demand. To help with your job search, we've compiled a guide to sales and marketing jobs in the life sciences industry.
Fierce Pharma
JANUARY 13, 2023
AstraZeneca pulls leukemia drug Lumoxiti off market after disappointing sales. Fri, 01/13/2023 - 09:29.
Pharmaceutical Technology
MARCH 30, 2023
The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. This would make Leqembi’s forecast sales 17 times greater than those of Aricept.
Bio Pharma Dive
MAY 5, 2022
The biotech reported positive results from a study meant to expand Vyvgart's use to another immune disorder, while sales from the drug's first quarter on the market exceeded expectations.
Bio Pharma Dive
MARCH 13, 2023
In its first full quarter on the market, Amylyx’s Relyvrio generated revenue just shy of $22 million, or roughly five times what some analysts were forecasting a month ago.
Fierce Pharma
JANUARY 3, 2024
Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales. Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales.
World of DTC Marketing
APRIL 6, 2022
DTC marketing has evolved. Challenge #1 – DIGITAL MARKETING. Pharma companies are increasing digital budgets, but they are wasting too much money because of internal staffing issues and inexperience with online marketing. Paid Media – The most commonly used KPI in marketing is essentially worthless.
Pharmaceutical Technology
FEBRUARY 8, 2023
The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 Pfizer maintained its third-place position in the market in 2022, reporting a market capitalization of $287.6 witnessed the biggest market capitalization growth of 45.3% trillion to $3.61 billion on Dec 31, 2022.
Bio Pharma Dive
MARCH 15, 2022
Instead of sharing global profits and losses, Eisai will receive royalties tied to net sales of the Alzheimer's drug. Biogen, meanwhile, said the amended deal should make it easier to "address market developments."
Bio Pharma Dive
OCTOBER 31, 2023
The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID vaccine sales.
Intouch Solutions
MAY 26, 2023
Even as some of the effects of COVID-19 have begun to wane, it’s a challenging time to be a life-sciences sales representative. Technology was supposed to bring on a new future for the sales interaction: greater insight into the customer, leading to better and more effective interactions. How can we do better?
World of DTC Marketing
NOVEMBER 16, 2021
SUMMARY: Omnichannel marketing employs the simultaneous implementation of channels across personal, non-personal, and media and addresses the integrated needs of multiple stakeholders – consumers/patients, healthcare professionals, and payers. Today there are microsegments of markets, and one message shouldn’t be used for all.
Pharmaceutical Technology
DECEMBER 15, 2022
In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. of sales in 2021 and 2031 respectively.
Pharmaceutical Technology
FEBRUARY 8, 2024
Abilify Maintena is approaching a significant market shift with the loss of market exclusivity in Europe and the US in October 2024.
BioSpace
SEPTEMBER 23, 2021
There are roughly 750 sales representatives for Amarin at present, which the company intends to whittle down to 300 as it adopts a more digital approach to marketing.
World of DTC Marketing
JANUARY 14, 2021
SUMMARY : Digital marketing is not a tactic. This will carry over to DTC marketing as well but simply adding more money is not going to equal success. To master digital marketing, pharma needs to be prepared to fail. To master digital marketing, pharma needs to be prepared to fail. Will digital replace the sales force?
Fierce Pharma
AUGUST 3, 2023
Even as Moderna chugs through another post-pandemic year, the biotech has raised its COVID-19 vaccine revenue projection in the expectation that it can deliver a strong showing in the private marke | The company raised its forecast for COVID-19 sales to between $6 billion and $8 billion, up from a prior estimate of $5 billion.
Drug Discovery World
JUNE 1, 2023
Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs $2.5 Using marketed treatments as a proxy, BI is expecting ex-US markets to have a 30-40% contribution within five years of launch. billion in 2022, with just under 70% stemming from the US.
Bio Pharma Dive
DECEMBER 5, 2022
The positive results could help Novartis secure approval for earlier use of the radiopharmaceutical drug Pluvicto, potentially broadening the number of eligible patients by several times the current market.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content